Barclays PLC Increases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Barclays PLC grew its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 279.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,580 shares of the biopharmaceutical company’s stock after acquiring an additional 48,316 shares during the period. Barclays PLC owned about 0.13% of Theravance Biopharma worth $529,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP raised its holdings in Theravance Biopharma by 38.4% during the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock worth $2,800,000 after purchasing an additional 91,679 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after buying an additional 143,781 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Theravance Biopharma by 83.6% during the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after buying an additional 135,426 shares during the last quarter. GSA Capital Partners LLP boosted its position in shares of Theravance Biopharma by 12.6% in the 3rd quarter. GSA Capital Partners LLP now owns 229,780 shares of the biopharmaceutical company’s stock worth $1,852,000 after buying an additional 25,691 shares in the last quarter. Finally, Bank of Montreal Can grew its stake in Theravance Biopharma by 141.0% in the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock valued at $1,414,000 after acquiring an additional 93,702 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Insider Activity

In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now owns 322,743 shares of the company’s stock, valued at $2,904,687. The trade was a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 6.90% of the company’s stock.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH opened at $8.58 on Friday. The firm’s 50-day moving average is $9.46 and its two-hundred day moving average is $8.89. The company has a market capitalization of $421.88 million, a PE ratio of -8.50 and a beta of 0.21. Theravance Biopharma, Inc. has a 12-month low of $7.44 and a 12-month high of $10.44.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). The company had revenue of $16.87 million during the quarter, compared to analysts’ expectations of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. During the same period in the previous year, the company posted ($0.17) EPS. On average, analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.